The activated HSCs can be reverted to quiescent HSCs by MDI treatment.
NLRC5 expressed differentially during different stages of hepatic fibrosis and its reversal.
Enforced NLRC5 in reverted LX-c cells boosted the expression of α-SMA and Col1α1.
Blockade of NLRC5 diminished α-SMA and Col1α1 expression.
NLRC5 might provide a novel therapeutic approach for liver fibrosis.